NCT06919679Not yet recruitingPhase 2
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 9 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 2 Apr 2025
- Start date
- Aug 2025
- Primary completion date
- Jan 2028
- Lead sponsor
- University of Cologne
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06919679
- EU CT number
- 2025-521749-26-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 35
- From Aug 2025 to the primary completion date, Jan 2028
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Multi-drug resistant HIV infection or concurrent AIDS-defining conditions
Other illness
- Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment
Lab values
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Histologically confirmed first diagnosis of cHL
- Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV
- No previous treatment for HL with the exception of steroid prephase
- Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or \> 250/μL at any time within 8 months prior to HL diagnosis
- Continuation of antiretroviral treatment (ART) / Initiation of ART in patients who are ART-naive
- Age: 18-60 years
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH Coordinator of this site? Confirm its status | Berlin | Germany | Not yet recruiting |
| Gesundheit Nord gGmbH Klinikverbund Bremen Coordinator of this site? Confirm its status | Bremen | Germany | Not yet recruiting |
| Universitaetsklinikum Koeln AöR Coordinator of this site? Confirm its status | Cologne | Germany | Not yet recruiting |
| Universitaetsklinikum Essen (AoR) Coordinator of this site? Confirm its status | Essen | Germany | Not yet recruiting |
| University Medical Center Hamburg-Eppendorf Coordinator of this site? Confirm its status | Hamburg | Germany | Not yet recruiting |
| Universitaetsklinikum Heidelberg AöR Coordinator of this site? Confirm its status | Heidelberg | Germany | Not yet recruiting |
| Rotkreuzklinikum Muenchen gGmbH Coordinator of this site? Confirm its status | Munich | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.